Literature DB >> 26223873

Correlation of Bone Mineral Parameters with Anthropometric Measurements and the Effect of Glucocorticoids on Bone Mineral Parameters in Congenital Adrenal Hyperplasia.

Ramaswamy Ganesh1, Natarajan Suresh2, Lalitha Janakiraman2, Karnam Ravikumar3.   

Abstract

OBJECTIVE: To correlate the bone mineral parameters [bone mineral content (BMC) and bone mineral density (BMD)] using Dual energy X ray Absorptiometry (DXA) scan with anthropometric measurements and to study the effect of glucocorticoid therapy on BMC/BMD in children with Congenital adrenal hyperplasia (CAH).
METHODS: A cross-sectional study was carried out in the Pediatric Endocrinology unit from January 2012 through March 2013 at Kanchi Kamakoti CHILDS Trust hospital, Chennai. Thirteen CAH children aged 0-132 mo with classic salt wasting due to 21 hydroxylase deficiency were included in the study. All children were treated with T.hydrocortisone @10-15 mg/m(2)/d twice daily and T. fludrocortisone 50 μg once daily orally at the time of enrollment into the study. The duration of glucocorticoid (hydrocortisone) treatment from the date of diagnosis till the time of enrollment into the study was noted and categorized as children receiving < 5 and > 5 y of glucocorticoid therapy. None received Vitamin D/calcium supplementation at the time of enrollment. BMC and areal BMD for the lumbar spine and total body less head (TBLH) were measured with Lunar DXA machine.
RESULTS: The mean height, weight and BMI of children were 87.3 ± 33 cm, 13.49 ± 11.2 kg and 14 ± 4.07 kg/m(2) respectively. TBLH BMC was 369.14 ± 312.18 g and TBLH BMD was 0.63 ± 0.11 g/cm(2). There was a significant correlation between height and total body less head BMC/BMD in the index series [P < 0.05, significant]. The TBLH and spine BMD were also assessed with regards to the duration of glucocorticoid therapy and it has been observed that TBLH and spine BMD decreased with increased duration of steroid therapy (p < 0.05, significant).
CONCLUSIONS: In the absence of normative data or z scores, BMC/BMD correlates well with height for age. Children who received more than 5 y of glucocorticoid treatment had lower TBLH and spine BMD scores and hence, calcium and Vitamin D supplementation should be considered.

Entities:  

Keywords:  Bone mineral content; Bone mineral density; Children; Congenital adrenal hyperplasia; Dual energy X ray absorptiometry

Mesh:

Substances:

Year:  2015        PMID: 26223873     DOI: 10.1007/s12098-015-1835-y

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  16 in total

1.  Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients.

Authors:  I R Reid; M C Evans; D J Wattie; R Ames; T F Cundy
Journal:  Osteoporos Int       Date:  1992-03       Impact factor: 4.507

2.  Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia.

Authors:  M Gussinyé; A Carrascosa; N Potau; M Enrubia; E Vicens-Calvet; L Ibáñez; D Yeste
Journal:  Pediatrics       Date:  1997-10       Impact factor: 7.124

3.  Height, bone mineral density and bone markers in congenital adrenal hyperplasia.

Authors:  C Paganini; G Radetti; C Livieri; V Braga; D Migliavacca; S Adami
Journal:  Horm Res       Date:  2000

4.  The effect of glucocorticoid replacement therapy on bone mineral density in children with congenital adrenal hyperplasia.

Authors:  Semra Cetinkaya; Cengiz Kara
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

5.  The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia.

Authors:  R Girgis; J S Winter
Journal:  J Clin Endocrinol Metab       Date:  1997-12       Impact factor: 5.958

6.  Determinants of bone mineral content and bone area in Indian preschool children.

Authors:  Veena H Ekbote; Anuradha V Khadilkar; Shashi A Chiplonkar; Vaman V Khadilkar
Journal:  J Bone Miner Metab       Date:  2010-10-13       Impact factor: 2.626

7.  Bone health should be an important concern in the care of patients affected by 21 hydroxylase deficiency.

Authors:  Anne Bachelot; Zeina Chakhtoura; Dinane Samara-Boustani; Jérome Dulon; Philippe Touraine; Michel Polak
Journal:  Int J Pediatr Endocrinol       Date:  2010-09-28

Review 8.  Steroid 21 hydroxylase deficiency congenital adrenal hyperplasia.

Authors:  Saroj Nimkarn; Karen Lin-Su; Maria I New
Journal:  Endocrinol Metab Clin North Am       Date:  2009-12       Impact factor: 4.741

9.  Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency.

Authors:  Zeina Chakhtoura; Anne Bachelot; Dinane Samara-Boustani; Jean-Charles Ruiz; Bruno Donadille; Jérôme Dulon; Sophie Christin-Maître; Claire Bouvattier; Marie-Charles Raux-Demay; Philippe Bouchard; Jean-Claude Carel; Juliane Leger; Frédérique Kuttenn; Michel Polak; Philippe Touraine
Journal:  Eur J Endocrinol       Date:  2008-04-07       Impact factor: 6.664

Review 10.  The Official Positions of the International Society for Clinical Densitometry: body composition analysis reporting.

Authors:  Steven Petak; Carmen G Barbu; Elaine W Yu; Roger Fielding; Kathleen Mulligan; Brian Sabowitz; Chih-Hsing Wu; John A Shepherd
Journal:  J Clin Densitom       Date:  2013 Oct-Dec       Impact factor: 2.617

View more
  2 in total

1.  Correlation of Bone Mineral Parameters with Anthropometric Measurements and the Effect of Glucocorticoids on Bone Mineral Parameters in Congenital Adrenal Hyperplasia: Correspondence.

Authors:  Aashima Dabas
Journal:  Indian J Pediatr       Date:  2016-05-24       Impact factor: 1.967

2.  Correlation of Bone Mineral Parameters with Anthropometric Measurements and the Effect of Glucocorticoids on Bone Mineral Parameters in Congenital Adrenal Hyperplasia: Authors' Reply.

Authors:  Ramaswamy Ganesh; Natarajan Suresh; Lalitha Janakiraman; Karnam Ravikumar
Journal:  Indian J Pediatr       Date:  2016-05-24       Impact factor: 1.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.